Neuland Labs Q3FY26 Revenue at ₹447.8 Cr, EBITDA Declines 5.9% YoY
Neuland Laboratories reported Q3FY26 total income of ₹447.8 crore, up 11.4% YoY. EBITDA was ₹85.0 crore, down 5.9% YoY, with margins at 19.0%. PAT stood at ₹40.4 crore, a 60.2% decrease. Management cited product mix and operating expenses for subdued margins, while highlighting long-term investments and growing customer interest.
The results show a decline in profitability metrics (EBITDA, PAT) and margins, which could be viewed negatively by investors. However, the revenue growth and management's commentary on future opportunities suggest a neutral to slightly positive outlook, warranting a medium impact.
While revenue saw a year-on-year increase, the significant decline in EBITDA and Profit After Tax, along with reduced margins, indicates a mixed financial performance. Management commentary acknowledges challenges but also points to future growth drivers.
Neuland Laboratories Limited announced its financial results for the quarter and nine months ended December 31, 2025. The company reported a Total Income of ₹447.8 crore for Q3FY26, an increase of 11.4% compared to ₹401.9 crore in Q3FY25. However, EBITDA for the quarter stood at ₹85.0 crore, a decrease of 5.9% from ₹90.3 crore in the same period last year. The EBITDA margin also saw a decline, falling to 19.0% in Q3FY26 from 22.5% in Q3FY25.
For the nine months ended December 31, 2025, the total income was ₹1264.5 crore, with an EBITDA of ₹284 crore. The company's Profit Before Tax (PBT) for Q3FY26 was ₹54.3 crore, a significant decrease of 57.4% from ₹127.5 crore in Q3FY25. Consequently, Profit After Tax (PAT) also fell to ₹40.4 crore from ₹101.4 crore year-on-year.
Commenting on the performance, Mr. Sucheth Davuluri, Vice-Chairman and Chief Executive Officer, stated that revenues were in line with the outlook, but product mix and increased operating expenses reflected subdued EBITDA margins. He emphasized continued business momentum and long-term investments to capitalize on growth opportunities.
Mr. Saharsh Davuluri, Vice Chairman and Managing Director, added that there is increasing interest from customers for their capabilities as a commercial NCE drug substance manufacturer and innovation partner. Investments are leading to more engagements with existing customers and attracting new ones seeking niche capabilities.
Neuland Laboratories Limited will conduct an Earnings Call at 17:30 hrs IST on Monday, February 9, 2025, to discuss the company's performance. The transcript of the conference call will be uploaded on the company website in due course.
What to do with a filing like this
Neuland Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Neuland Laboratories Limited. Read the original for the full detail.